RxDoctor Payments Data

Scott Varga, MD

Neurology · Dublin, OHNPI 1528593043

Payments from drug & device makers

$32,975in general payments, 2019–2025

Across 57 payments — averaging $578.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$33K
  • UCB, Inc.$136
  • Amgen$48
  • Argenx US, Inc.$27
  • Biohaven Pharmaceutical Holding Company Ltd.$26
  • Amneal Pharmaceuticals LLC$21
  • plus $108 from 6 others

What the payments were for

  • Speaking & faculty fees$31,26995%
  • Travel & lodging$770%
  • Food & beverage$1,6305%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,975 in reported general payments places this provider in the 75th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$179,819
Medicare patients
394
Services billed
13,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$150,558
OctagamImmun Globg(Igg)/Malt/Iga Ov5034$111,892
Aimovig AutoinjectorErenumab-Aooe86$73,088
UbrelvyUbrogepant49$65,376
Nurtec OdtRimegepant Sulfate45$61,121
QuliptaAtogepant45$49,709
GlatopaGlatiramer Acetate14$37,632
Ajovy AutoinjectorFremanezumab-Vfrm31$29,893
AptiomEslicarbazepine Acetate11$13,432
Carbidopa-LevodopaCarbidopa/Levodopa285$12,996
MyrbetriqMirabegron16$9,202
Emgality PenGalcanezumab-Gnlm11$7,630
Propranolol Hcl ErPropranolol Hcl92$4,718
Levetiracetam134$4,068
Pregabalin96$3,514

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$15$173,01279 claims
Teva Pharmaceuticals USA, Inc.Austedo$17$150,55813 claims
AbbVieUbrelvy, Qulipta$32,610$115,08694 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$21$5,29242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 702 neurology providers in Ohio.

Other neurology in Dublin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →